Please assess the completion status of the following clinical trial:

Trial Title: Study of Low Level Laser Therapy to Treat Diabetic Peripheral Neuropathy Foot Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Existing clinical diagnosis of diabetes induced Peripheral Neuropathy documented by a suitably qualified and licensed medical professional~* Significant spontaneous foot pain that occurs approximately equally (comparably) bilaterally~* Significant spontaneous pain of 50 or greater on the 0-100 Visual Analog Scale (VAS) for the feet overall~* Foot pain is chronic, defined as having been ongoing for at least 3 months, bilaterally~* Stable anti-diabetic medication regimen for the prior 30 days or on no anti-diabetic medication regimen for the prior 30 days~* Willing and able to refrain from consuming any non-study over-the-counter and/or prescription medications or therapies for the relief of pain/inflammation throughout study participation~* Primary language is English.~Exclusion Criteria:~* No definitive clinical diagnosis of diabetes induced Peripheral Neuropathy or foot pain is undiagnosed, or diagnosed as being other than, or in addition to, diabetes induced Peripheral Neuropathy~* Foot pain is unilateral or notably different between the two feet~* Self-reported Degree of Pain rating on the Visual Analog Scale (VAS) pain scale is less than 50 for both feet overall~* Serious organ disease or other serious primary disease merger~* Diabetes ketosis, ketoacidosis or severe infection within the past 2 weeks~* Current, active chronic pain disease~* Cancer or treatment for cancer in the past 6 months~* Use of any analgesics, or an equivalent of over-the counter or prescription NSAIDs (nonsteroidal anti-inflammatory drugs) within 7 days prior to study initiation~* Use of any antidepressants within 30 days prior to study initiation~* Use of any of the following prescription medications within 30 days prior to study initiation: Neurontin; Lyrica; Tramadol; Opioid medicines such as Ultram and Ultracet~* Injections of local anesthetics such as lidocaine within the past 30 days~* Surgical intervention to treat diabetic peripheral neuropathy foot pain, including implantation of a pain relief device~* Active infection, wound or other external trauma to the treatment areas~* Medical, physical, or other contraindications for, or sensitivity to, light therapy~* Pregnant, breast feeding, or planning pregnancy prior to the end of study participation~* Serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in past two years~* Developmental disability or cognitive impairment that in the opinion of the investigator would preclude adequate comprehension of the consent form and/or ability to record study measurements~* Involvement in litigation/receiving disability benefits related to the parameters of the study~* Participation in other research in the past 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erchonia® FX-635™ (Type: ACTIVE_COMPARATOR): The Erchonia® FX-635™ is made up of 3 independent 17 milliWatts (mW), 635 nanometers (nm) red laser diodes mounted in scanner devices with flexible arms positioned equidistant from each other.
- Placebo Laser (Type: PLACEBO_COMPARATOR): The Placebo Laser has the same appearance as the Erchonia® FX-635™ but does not emit any therapeutic light.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete